Goldman Sachs maintains APA (NASDAQ:APA) with a Neutral and lowers the price target from $52 to $41.
Merck’s Keytruda Phase 3 Trial Meets Primary Endpoint In Gastric Cancer Patients
Merck & Co Inc (NYSE:MRK) has announced topline results from the pivotal Phase 3 KEYNOTE-859 trial of its flagship anti-PD-1 therapy,…